Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2019 2
2020 3
2021 4
2022 2
2023 4
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Results by year

Filters applied: . Clear all
Page 1
Baseline PET radiomics outperforms the IPI risk score for prediction of outcome in diffuse large B-cell lymphoma.
Eertink JJ, Zwezerijnen GJC, Heymans MW, Pieplenbosch S, Wiegers SE, Dührsen U, Hüttmann A, Kurch L, Hanoun C, Lugtenburg PJ, Barrington SF, Mikhaeel NG, Ceriani L, Zucca E, Czibor S, Györke T, Chamuleau MED, Hoekstra OS, de Vet HCW, Boellaard R, Zijlstra JM. Eertink JJ, et al. Among authors: pieplenbosch s. Blood. 2023 Jun 22;141(25):3055-3064. doi: 10.1182/blood.2022018558. Blood. 2023. PMID: 37001036 Free PMC article.
An artificial intelligence method using FDG PET to predict treatment outcome in diffuse large B cell lymphoma patients.
Ferrández MC, Golla SSV, Eertink JJ, de Vries BM, Lugtenburg PJ, Wiegers SE, Zwezerijnen GJC, Pieplenbosch S, Kurch L, Hüttmann A, Hanoun C, Dührsen U, de Vet HCW; PETRA; Zijlstra JM, Boellaard R. Ferrández MC, et al. Among authors: pieplenbosch s. Sci Rep. 2023 Aug 12;13(1):13111. doi: 10.1038/s41598-023-40218-1. Sci Rep. 2023. PMID: 37573446 Free PMC article.
Baseline radiomics features and MYC rearrangement status predict progression in aggressive B-cell lymphoma.
Eertink JJ, Zwezerijnen GJC, Wiegers SE, Pieplenbosch S, Chamuleau MED, Lugtenburg PJ, de Jong D, Ylstra B, Mendeville M, Dührsen U, Hanoun C, Hüttmann A, Richter J, Klapper W, Jauw YWS, Hoekstra OS, de Vet HCW, Boellaard R, Zijlstra JM. Eertink JJ, et al. Among authors: pieplenbosch s. Blood Adv. 2023 Jan 24;7(2):214-223. doi: 10.1182/bloodadvances.2022008629. Blood Adv. 2023. PMID: 36306337 Free PMC article.
18F-FDG PET Improves Baseline Clinical Predictors of Response in Diffuse Large B-Cell Lymphoma: The HOVON-84 Study.
Burggraaff CN, Eertink JJ, Lugtenburg PJ, Hoekstra OS, Arens AIJ, de Keizer B, Heymans MW, van der Holt B, Wiegers SE, Pieplenbosch S, Boellaard R, de Vet HCW, Zijlstra JM; HOVON Imaging Working Group and the HOVON Lymphoma Working Group. Burggraaff CN, et al. Among authors: pieplenbosch s. J Nucl Med. 2022 Jul;63(7):1001-1007. doi: 10.2967/jnumed.121.262205. Epub 2021 Oct 21. J Nucl Med. 2022. PMID: 34675112 Free PMC article. Clinical Trial.
Optimal timing and criteria of interim PET in DLBCL: a comparative study of 1692 patients.
Eertink JJ, Burggraaff CN, Heymans MW, Dührsen U, Hüttmann A, Schmitz C, Müller S, Lugtenburg PJ, Barrington SF, Mikhaeel NG, Carr R, Czibor S, Györke T, Ceriani L, Zucca E, Hutchings M, Kostakoglu L, Loft A, Fanti S, Wiegers SE, Pieplenbosch S, Boellaard R, Hoekstra OS, Zijlstra JM, de Vet HCW. Eertink JJ, et al. Among authors: pieplenbosch s. Blood Adv. 2021 May 11;5(9):2375-2384. doi: 10.1182/bloodadvances.2021004467. Blood Adv. 2021. PMID: 33944897 Free PMC article.
Interobserver reproducibility of tumor uptake quantification with 89Zr-immuno-PET: a multicenter analysis.
Jauw YWS, Bensch F, Brouwers AH, Hoekstra OS, Zijlstra JM, Pieplenbosch S, Schröder CP, Zweegman S, van Dongen GAMS, Menke-van der Houven van Oordt CW, de Vries EGE, de Vet HCW, Boellaard R, Huisman MC. Jauw YWS, et al. Among authors: pieplenbosch s. Eur J Nucl Med Mol Imaging. 2019 Aug;46(9):1840-1849. doi: 10.1007/s00259-019-04377-6. Epub 2019 Jun 17. Eur J Nucl Med Mol Imaging. 2019. PMID: 31209514 Free PMC article.
14 results